Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K6SM
|
|||
| Former ID |
DCL000132
|
|||
| Drug Name |
Ilepatril
|
|||
| Indication | Diabetic nephropathy [ICD-11: GB61.Z] | Discontinued in Phase 2/3 | [1] | |
| Heart failure [ICD-11: BD10-BD13] | Discontinued in Phase 2/3 | [1] | ||
| Hypertension [ICD-11: BA00-BA04] | Discontinued in Phase 2/3 | [1] | ||
| Renal failure [ICD-11: GB60-GB6Z] | Discontinued in Phase 2/3 | [1] | ||
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H28N2O5S
|
|||
| Canonical SMILES |
CC(C)C(C(=O)NC1CC2=CC=CC=C2C3CCCC(N3C1=O)C(=O)O)SC(=O)C
|
|||
| InChI |
1S/C22H28N2O5S/c1-12(2)19(30-13(3)25)20(26)23-16-11-14-7-4-5-8-15(14)17-9-6-10-18(22(28)29)24(17)21(16)27/h4-5,7-8,12,16-19H,6,9-11H2,1-3H3,(H,23,26)(H,28,29)/t16-,17+,18-,19-/m0/s1
|
|||
| InChIKey |
FXKFFTMLFPWYFH-RDGPPVDQSA-N
|
|||
| CAS Number |
CAS 473289-62-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiotensin-converting enzyme (ACE) | Target Info | Modulator | [1] |
| Neutral endopeptidase (MME) | Target Info | Modulator | [1] | |
| KEGG Pathway | Renin-angiotensin system | |||
| Hematopoietic cell lineage | ||||
| Protein digestion and absorption | ||||
| Alzheimer's disease | ||||
| Chagas disease (American trypanosomiasis) | ||||
| Hypertrophic cardiomyopathy (HCM) | ||||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Angiotensin Metabolism | |||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | Metabolism of Angiotensinogen to Angiotensins | |||
| Primary Focal Segmental Glomerulosclerosis FSGS | ||||
| Alzheimers Disease | ||||
| ACE Inhibitor Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs. 2008 Mar;9(3):301-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.